Kymera’s pill looks competitive to Dupixent in Phase 1b eczema studynews2025-12-08T12:00:59+00:00December 8th, 2025|Endpoints News|
Kallyope heads to Phase 3 with migraine drug after mid-stage successnews2025-12-08T11:30:40+00:00December 8th, 2025|Endpoints News|
#ASH25: Star Therapeutics details early data for blood disorder shot, weighs IPOnews2025-12-07T21:57:35+00:00December 7th, 2025|Endpoints News|
#ASH25: AstraZeneca’s dual-targeting CAR-T sees similar responses in Western patients as in Chinanews2025-12-06T20:00:15+00:00December 6th, 2025|Endpoints News|
#ASH25: As one door closes for Regeneron’s lymphoma bispecific, another reopensnews2025-12-06T14:30:29+00:00December 6th, 2025|Endpoints News|
Apple Tree Partners scores legal win against alleged holdout Russian investornews2025-12-06T11:37:53+00:00December 6th, 2025|Endpoints News|
ACIP vote, more FDA turnover; Introducing Endpoints Signal; ARCH, Parker Institute building next cancer bet; and morenews2025-12-06T11:00:06+00:00December 6th, 2025|Endpoints News|
ORIC’s lung cancer pill shows promise in some settings but is dropped for HER2 mutationsnews2025-12-06T01:00:15+00:00December 6th, 2025|Endpoints News|
Bristol Myers expands Breyanzi approval to marginal zone lymphomanews2025-12-05T19:17:02+00:00December 5th, 2025|Endpoints News|
ACIP drops universal hepatitis B birth dose recommendationnews2025-12-05T16:52:18+00:00December 5th, 2025|Endpoints News|
